Palleon's first CSO explains how they (and she) got here; Enterprise taps Roche and Novartis vet David Morris as CMO
For a decade, Li Peng built antibodies at the MedImmune labs outside DC: A bispecific Amgen is now testing in GI cancer, an Il-5 for certain kinds of asthma, another that impacts natural killer cells near tumors.
It was a sensible approach. The first antibody to treat cancer was introduced not long before she began grad school and the hunt has played a major role in biotech for much of Peng’s career.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 147,200+ biopharma pros reading Endpoints daily — and it's free.